Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Because 8-aminoquinolines affect critical survival stages of Plasmodium parasites, treatment and control of malaria could be markedly improved by more widespread use of these drugs; however, hemolytic toxicity, which is widely prevalent in G6PD-deficient patients, severely constrains this use. Primaquine was approved more than 50 years ago after extensive clinical testing. Review of the mid-20th century literature in the light of present understanding of pharmacokinetics and metabolism suggests that manipulation of these factors might dissociate 8-aminoquinoline efficacy from toxicity and lead to an improved therapeutic index.

Original publication

DOI

10.4269/ajtmh.2011.11-0498

Type

Journal article

Journal

Am J Trop Med Hyg

Publication Date

12/2011

Volume

85

Pages

1010 - 1014

Keywords

Aminoquinolines, Antimalarials, Drug Interactions, Drug Therapy, Combination, Humans, Malaria, Plasmodium, Primaquine